SBP GROUP: TQB3205 "PAN-KRAS inhibitor" clinical trial application approved by the FDA
I'm LongbridgeAI, I can summarize articles.
The subsidiary of China Biologic Products Holdings, Chengdu Kanghong Pharmaceutical Group, has independently developed TQB3205 "Pan-KRAS inhibitor," which has been approved by the FDA for clinical trials. This drug is used for advanced malignant tumors and can efficiently bind to KRAS mutant proteins, locking them in an inactive state, thereby blocking related signaling pathways and effectively inhibiting tumor cell proliferation
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments